Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OTLK | 8-K | bearish | 6/10 | Outlook Therapeutics priced a $55.0M registered direct offering of 55,555,556 shares of common stock and accompanying wa | Aug 14, 2026 |
| DKL | 8-K | bearish | 5/10 | Delek Logistics Partners (DKL) priced a public offering of 4,000,000 common units at $50.00 per unit, with an underwrite | Aug 14, 2026 |
| PFS | 8-K | neutral | 2/10 | Provident Financial Services filed an 8-K furnishing a fixed income investor presentation dated August 14, 2026. The pre | Aug 14, 2026 |
| VTGN | 8-K | bearish | 6/10 | Vistagen reported Q1 FY2027 net loss of $13.0M ($0.30/share), slightly missing the $0.29 consensus. Revenue of $1.5M was | Aug 14, 2026 |
| MBRX | 8-K | bullish | 7/10 | Moleculin Biotech reported Q2 2026 results highlighting positive interim MIRACLE trial data showing complete remission r | Aug 14, 2026 |
| NGTF | 8-K | neutral | 4/10 | NightFood Holdings filed an 8-K detailing a governance overhaul: two directors resigned (Lei Sonny Wang and Thomas Morse | Aug 14, 2026 |
| CRNX | 8-K | bullish | 6/10 | Vertex's acquisition of Crinetics cleared all major antitrust hurdles: HSR waiting period expired August 12, and approva | Aug 14, 2026 |
| CLYM | 8-K | neutral | 3/10 | Climb Bio announced that the first patient has been dosed in a Phase 2 clinical trial for immunoglobulin A nephropathy ( | Aug 14, 2026 |
| CLNN | 8-K | mixed | 6/10 | Clene reported Q2 2026 results with a net loss of $13.4M ($1.08/share), widening from $7.4M ($0.78/share) a year ago, dr | Aug 14, 2026 |
| MYSZ | 8-K | mixed | 5/10 | My Size reported Q2 2026 revenue of $3.07M (+53% YoY), driven by e-commerce and Percentil growth, but gross margin colla | Aug 14, 2026 |
| ROC | 8-K | mixed | 5/10 | ROC reported Q2 2026 revenue of $5.1M, up 2% YoY and 100% sequentially, with gross margin expanding to 90% from 80%. How | Aug 14, 2026 |
| OBAI | 8-K | neutral | 2/10 | Our Bond, Inc. (OBAI) filed an 8-K announcing that CEO Doron Kempel will host a live webinar on August 14, 2026, at 11:0 | Aug 14, 2026 |
| WHLR | 8-K | neutral | 3/10 | Wheeler Real Estate Investment Trust appointed Jason F. Simone as Chief Financial Officer, effective August 10, 2026, pr | Aug 14, 2026 |
| SPCX | 8-K | bullish | 7/10 | Space Exploration Technologies Corp. (SPCX) completed its $60.0 billion all-stock acquisition of Anysphere, Inc. (Cursor | Aug 14, 2026 |
| IPDN | 8-K | bearish | 6/10 | IPDN reported Q2 2026 revenue of $1.181M, down 28% YoY, with net loss widening to $1.716M driven by $1.193M in amortizat | Aug 14, 2026 |
| LEAT | 8-K | mixed | 5/10 | Leatt Corp reported Q2 2026 revenue of $16.39M, up 1% YoY, while net income fell 20% to $0.91M, citing temporary supply | Aug 14, 2026 |
| QNCX | 8-K | neutral | 5/10 | Quince Therapeutics reported Q2 2026 results reflecting the transformational acquisition of Orphai Therapeutics and a co | Aug 14, 2026 |
| SHC | 8-K | neutral | 2/10 | Director James C. Neary resigned from Sotera Health's board effective August 13, 2026, with no disagreement cited. The b | Aug 14, 2026 |
| DEC | 8-K | neutral | 4/10 | Diversified Energy issued an RNS response on August 14, 2026 confirming it has held preliminary, early-stage discussions | Aug 14, 2026 |
| CORZ | 8-K | bullish | 6/10 | Core Scientific completed its previously announced acquisition of Polaris DS LLC for approximately $444.3 million in cas | Aug 14, 2026 |
| STDN | 8-K | neutral | 2/10 | Standard Nuclear expanded its board from four to five directors and appointed Seth Cohen, former U.S. DOE Chief Counsel | Aug 14, 2026 |
| SEV | 8-K | neutral | 2/10 | Aptera Motors expanded its board from four to five members and appointed Wellington J. Reiter as an independent director | Aug 14, 2026 |
| WU | 8-K | mixed | 5/10 | Western Union and Intermex (IMXI) secured NYDFS approval for their pending merger, agreeing to three-year commitments on | Aug 14, 2026 |
| RMIX | 8-K | mixed | 6/10 | Suncrete reported Q2 2026 revenue of $97.2M (+146% YoY), well above the $101.5M consensus, but GAAP net loss widened to | Aug 14, 2026 |
| PMVP | 8-K | neutral | 5/10 | PMV Pharma reported Q2 2026 results with a net loss of $18.1M ($-0.34/share), beating consensus estimates of $-0.38. The | Aug 14, 2026 |
| BENF | 8-K | bullish | 6/10 | Beneficient reported Q1 FY2027 GAAP revenue of $12.2M (vs -$12.6M a year ago) and EPS of ($0.47), a 77% beat vs the cons | Aug 14, 2026 |
| VRME | 8-K | bearish | 5/10 | VerifyMe reported Q2 2026 revenue of $1.9M, a 58% YoY decline from $4.5M, continuing the revenue erosion from the Septem | Aug 14, 2026 |
| BKYI | 8-K | bearish | 6/10 | BIO-key reported Q2 2026 revenue of $1.9M (+13% YoY) and a net loss improvement to $(577K) from $(1.2M), but missed its | Aug 14, 2026 |
| EDBL | 8-K | mixed | 5/10 | Edible Garden reported Q2 2026 revenue of $3.55M (+12.8% YoY, beating $3.4M consensus) and a net loss improvement to $3. | Aug 14, 2026 |
| HURA | 8-K | neutral | 3/10 | TuHURA Biosciences reported Q2 2026 financial results with cash of $1.0M and operating cash outflow of $13.0M in H1 2026 | Aug 14, 2026 |